Skandinaviska Enskilda Banken AB publ acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 26,816 shares of the company's stock, valued at approximately $634,000.
Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after buying an additional 698 shares in the last quarter. KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after acquiring an additional 751 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $34,000. Virtue Capital Management LLC lifted its holdings in shares of Dyne Therapeutics by 4.4% during the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock valued at $834,000 after purchasing an additional 981 shares during the last quarter. Finally, Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 96.68% of the company's stock.
Insider Activity
In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 6,237 shares of company stock valued at $77,760. Insiders own 20.77% of the company's stock.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Chardan Capital reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday. Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Piper Sandler cut their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.46.
Check Out Our Latest Analysis on DYN
Dyne Therapeutics Price Performance
Shares of NASDAQ DYN traded down $0.18 during trading hours on Friday, hitting $12.08. 2,328,131 shares of the company's stock were exchanged, compared to its average volume of 1,342,074. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11. The company's 50-day moving average price is $13.68 and its 200-day moving average price is $24.49. Dyne Therapeutics, Inc. has a 1-year low of $11.18 and a 1-year high of $47.45.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.
About Dyne Therapeutics
(
Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
